Marcum Wealth LLC Has $312,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Marcum Wealth LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,545 shares of the biopharmaceutical company’s stock after selling 165 shares during the period. Marcum Wealth LLC’s holdings in Gilead Sciences were worth $312,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Private Wealth Management Group LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $29,000. Sachetta LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $30,000. Palisade Asset Management LLC acquired a new stake in Gilead Sciences during the first quarter worth approximately $29,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $33,000. Finally, Gladius Capital Management LP acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $34,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Robert W. Baird reissued a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. TD Cowen cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. UBS Group cut their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Maxim Group cut their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Twelve equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $81.81.

Gilead Sciences Stock Performance

GILD stock traded down $1.94 during midday trading on Monday, reaching $74.83. 7,347,882 shares of the company’s stock traded hands, compared to its average volume of 7,415,173. The firm has a market capitalization of $93.23 billion, a PE ratio of 208.28, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The company has a 50-day moving average price of $68.80 and a two-hundred day moving average price of $70.66. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.